Physician profile
Cassandra Garraud
NPI 1578192134
$2,213.96
in general payments reported to CMS, 2019-2025
18 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $719 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124 · Education: $90.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.72 |
| Education | $90.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $401.05 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $383.15 | 2024-2025 | |
| Edwards Lifesciences Corporation | $347.09 | 2024-2025 | Sapien 3 Ultra Resilia |
| Endologix LLC | $197.03 | 2025 | Endocross Device, Torus Stent Graft System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.02 | 2024 | Lifevest |
| Stryker Corporation | $146.20 | 2025 | Flowtriever, Clottriever Bold Catheter |
| Medtronic, INC. | $125.12 | 2025 | Symplicity G3 |
| Abbott Laboratories | $90.58 | 2025 | Mitraclip, Cardiomems |
| Abiomed | $81.69 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $55.23 | 2025 | |
| Becton, Dickinson and Company | $46.75 | 2025 | Hemosphere |
| Merck Sharp & Dohme LLC | $35.92 | 2024 | Verquvo |
| Boston Scientific Corporation | $33.90 | 2025 | Vigilant X4 Crt-D |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.33 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $25.32 | 2024 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $22.00 | 2024 | |
| Bridgebio Pharma, INC. | $18.68 | 2025 | Attruby |
| Chiesi USA, INC. | $13.90 | 2024 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Garraud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.